Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women
Details : Zilucoplan is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 08, 2025
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zilucoplan is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 19, 2024
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zilucoplan is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Myasthenia Gravis.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 24, 2024
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zilucoplan is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Myasthenia Gravis.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 30, 2024
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ZILBRYSQ® Now Available in The U.S. for Generalized Myasthenia Gravis
Details : Zilbrysq (zilucoplan), the first FDA-approved self-administered C5 complement inhibitor, treats generalized myasthenia gravis in anti-AChR antibody-positive adults.
Product Name : Zilbrysq
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
January 03, 2024
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zilbrysq (zilucoplan) is a C5 inhibitor peptide drug candidate, which is currently being evaluated for the treatment of patients with AChR antibody-positive generalized myasthenia gravis.
Product Name : Zilbrysq
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
December 04, 2023
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zilbrysq (zilucoplan) is a once-daily, SC, self-administered peptide inhibitor of complement component 5 (C5 inhibitor). As the only once-daily gMG target therapy for self-administration by adult patients with anti-AChR antibody-positive gMG.
Product Name : Zilbrysq
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
October 17, 2023
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zilucoplan is a Protein drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Myasthenia Gravis.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 28, 2023
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RA101495 (zilucoplan) is a once-daily SC, self-administered peptide inhibitor of complement component 5, which is investigated for the treatment of adults with generalized myasthenia gravis.
Product Name : Zilbrysq
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
September 15, 2023
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zilucoplan is a subcutaneous (SC), self-administered peptide inhibitor of complement component 5 (C5 inhibitor) for the treatment of adult patients with acetylcholine receptor antibody positive (AChR-Ab+) generalized myasthenia gravis (gMG).
Product Name : Zilbrysq
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
November 14, 2022
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable